Published in N Engl J Med on December 04, 2003
Graft-versus-host disease. Lancet (2009) 8.78
Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med (2008) 4.16
Interleukin-10: new perspectives on an old cytokine. Immunol Rev (2008) 3.94
Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity (2012) 2.99
Acute graft-versus-host disease: from the bench to the bedside. Blood (2009) 2.24
Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood (2007) 2.19
Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease. J Clin Oncol (2013) 2.07
Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood (2006) 2.06
Evaluation of published single nucleotide polymorphisms associated with acute GVHD. Blood (2012) 1.88
Interleukin-10 polymorphism in position -1082 and acute respiratory distress syndrome. Eur Respir J (2006) 1.82
Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol (2012) 1.49
Prediction of graft-versus-host disease in humans by donor gene-expression profiling. PLoS Med (2007) 1.40
Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis. Biol Blood Marrow Transplant (2014) 1.26
New approaches for preventing and treating chronic graft-versus-host disease. Blood (2005) 1.20
Interleukin-10: a multi-faceted agent of pregnancy. Am J Reprod Immunol (2010) 1.17
Type 1 regulatory T cells are associated with persistent split erythroid/lymphoid chimerism after allogeneic hematopoietic stem cell transplantation for thalassemia. Haematologica (2009) 1.12
Pathogenesis and management of graft-versus-host disease. Immunol Allergy Clin North Am (2010) 1.10
Association of serum interleukin-7 levels with the development of acute graft-versus-host disease. J Clin Oncol (2008) 1.07
Advances in predicting acute GVHD. Br J Haematol (2012) 1.07
Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Immunotherapy (2009) 1.07
Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res (2007) 1.06
Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-type antigen-presenting cells. Biol Blood Marrow Transplant (2008) 1.04
The contributions of normal variation and genetic background to mammalian gene expression. Genome Biol (2006) 1.01
Significance of ethnicity in the risk of acute graft-versus-host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2013) 1.00
Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation. Curr Opin Hematol (2010) 0.96
Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer. PLoS One (2012) 0.95
Current and future approaches for control of graft-versus-host disease. Expert Rev Hematol (2008) 0.95
Chronic graft-versus-host disease (GVHD) in children. Pediatr Clin North Am (2010) 0.94
Targeting regulatory T cells in the treatment of type 1 diabetes mellitus. Curr Mol Med (2012) 0.92
Association of IL-10 and IL-10Rbeta gene polymorphisms with graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling donor. BMC Immunol (2009) 0.92
IL10 and IL10 receptor gene variation and outcomes after unrelated and related hematopoietic cell transplantation. Transplantation (2009) 0.92
Biologic markers of chronic GVHD. Bone Marrow Transplant (2013) 0.91
Haplotype-independent costimulation of IL-10 secretion by SDF-1/CXCL12 proceeds via AP-1 binding to the human IL-10 promoter. J Immunol (2007) 0.90
The biology of graft-versus-host disease: experimental systems instructing clinical practice. Blood (2014) 0.90
NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: etiology and pathogenesis of late effects after HCT performed in childhood--methodologic challenges. Biol Blood Marrow Transplant (2011) 0.89
Human chorionic gonadotropin and indolamine 2,3-dioxygenase in patients with GVHD. Bone Marrow Transplant (2014) 0.89
Tumor necrosis factor polymorphism affects transplantation outcome in patients with myelodysplastic syndrome but not in those with chronic myelogenous leukemia, independent of the presence of HLA-DR15. Biol Blood Marrow Transplant (2010) 0.89
Mapping MHC-resident transplantation determinants. Biol Blood Marrow Transplant (2007) 0.89
Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation. Proc Natl Acad Sci U S A (2010) 0.88
Advances in the treatment of acute graft-versus-host disease. J Cell Mol Med (2013) 0.87
Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia. Haematologica (2010) 0.87
Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease. J Leukoc Biol (2012) 0.86
Graft-versus-host disease: a surge of developments. PLoS Med (2007) 0.84
Polymorphisms in the base excision repair pathway and graft-versus-host disease. Leukemia (2010) 0.84
Interleukin-10 spot-forming cells as a novel biomarker of chronic graft-versus-host disease. Haematologica (2012) 0.83
Serum proteomic profiling and haptoglobin polymorphisms in patients with GVHD after allogeneic hematopoietic cell transplantation. J Hematol Oncol (2009) 0.83
Haplotype-dependent differential activation of the human IL-10 gene promoter in macrophages and trophoblasts: implications for placental IL-10 deficiency and pregnancy complications. Am J Reprod Immunol (2010) 0.82
Interleukin-10: a pleiotropic regulator in pregnancy. Am J Reprod Immunol (2014) 0.82
Effect of cytokine and pharmacogenomic genetic polymorphisms in transplantation. Curr Opin Immunol (2008) 0.81
What are the most important donor and recipient factors affecting the outcome of related and unrelated allogeneic transplantation? Best Pract Res Clin Haematol (2008) 0.81
Interleukin-10 gene polymorphisms are associated with freedom from treatment failure for patients with Hodgkin lymphoma. Oncologist (2013) 0.81
Analysis of inflammation- and atherosclerosis-related gene polymorphisms in branch retinal vein occlusion. Mol Vis (2009) 0.80
New advances in hematopoietic cell transplantation. Curr Opin Hematol (2008) 0.80
IL-10 exacerbates xenogeneic GVHD by inducing massive human T cell expansion. Clin Immunol (2014) 0.80
Interleukin-1 alpha genotype and outcome of unrelated donor haematopoietic stem cell transplantation for chronic myeloid leukaemia. Br J Haematol (2007) 0.79
Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity. Proc Natl Acad Sci U S A (2012) 0.78
Analysis of non-HLA genomic risk factors in HLA-matched unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia. Haematologica (2012) 0.78
Genomic and proteomic analysis of allogeneic hematopoietic cell transplant outcome. Seeking greater understanding the pathogenesis of GVHD and mortality. Biol Blood Marrow Transplant (2009) 0.78
α-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics. Blood (2014) 0.78
Relationship between cytokine gene polymorphisms and recurrent spontaneous abortion. Int J Clin Exp Med (2015) 0.78
Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patients. Biol Blood Marrow Transplant (2014) 0.77
Interleukin-10 and graft-versus-host disease. N Engl J Med (2004) 0.77
Three-dimensional structure discrepancy between HLA alleles for effective prediction of aGVHD severity and optimal selection of recipient-donor pairs: a proof-of-concept study. Oncotarget (2015) 0.77
Predicting survival using clinical risk scores and non-HLA immunogenetics. Bone Marrow Transplant (2015) 0.76
Haplotype-tagging interleukin-10 promoter polymorphism is associated with reduced risk of retinal artery occlusion. Mol Vis (2007) 0.76
Cytokine gene polymorphisms and graft-versus-host disease in children after matched sibling hematopoietic stem cell transplantation: a single-center experience. Cell Mol Immunol (2011) 0.76
Combination of IL-10 and IL-2 induces oligoclonal human CD4 T cell expansion during xenogeneic and allogeneic GVHD in humanized mice. Heliyon (2017) 0.75
Impact of inflammatory cytokine gene polymorphisms on developing acute graft-versus-host disease in children undergoing allogeneic hematopoietic stem cell transplantation. J Immunol Res (2015) 0.75
The Relationship between STR-PCR Chimerism Analysis and Chronic GvHD Following Hematopoietic Stem Cell Transplantation. Int J Hematol Oncol Stem Cell Res (2017) 0.75
The evolving role of statins in hematopoietic stem and progenitor cell transplantation. Am J Blood Res (2011) 0.75
Interleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target. Front Immunol (2017) 0.75
Increased Level of IFN-γ and IL-4 Spot-Forming Cells on ELISPOT Assay as Biomarkers for Acute Graft-Versus-Host Disease and Concurrent Infections. Cells (2012) 0.75
Association of interleukin-10 gene promoter polymorphisms with recurrent pregnancy loss: a meta-analysis. J Assist Reprod Genet (2016) 0.75
A protective gene for graft-versus-host disease. N Engl J Med (2003) 0.75
Investigation of functional IL-10 gene polymorphism and IL-10 levels in acute graft-versus-host disease. J Clin Immunol (2010) 0.75
Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant. Blood (2017) 0.75
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood (2005) 10.63
Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med (2010) 7.20
Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med (2002) 6.20
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med (2008) 4.16
Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology (2014) 3.92
Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc Natl Acad Sci U S A (2011) 3.80
Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol (2010) 3.55
Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst (2005) 3.48
Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol (2011) 3.32
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood (2003) 3.30
Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst (2008) 3.27
Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med (2012) 3.20
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood (2003) 3.16
Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis (2008) 3.01
Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology (2003) 2.97
Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med (2013) 2.84
Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood (2004) 2.83
Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood (2004) 2.77
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood (2009) 2.73
Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma. JAMA (2004) 2.65
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant (2006) 2.63
Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. J Hepatol (2005) 2.58
Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol (2013) 2.58
A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology (2008) 2.55
Age group and sex differences in performance on a computerized neurocognitive battery in children age 8-21. Neuropsychology (2012) 2.54
Public stem cell banks: considerations of justice in stem cell research and therapy. Hastings Cent Rep (2004) 2.53
Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med (2003) 2.49
How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol (2007) 2.48
Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology (2008) 2.46
Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant (2006) 2.44
Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood (2009) 2.44
Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood (2008) 2.39
High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology (2012) 2.36
Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol (2007) 2.34
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood (2003) 2.33
Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2004) 2.32
Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood (2011) 2.26
Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood (2002) 2.23
Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood (2012) 2.19
P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology (2002) 2.18
Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology (2003) 2.15
Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol (2005) 2.15
Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol (2011) 2.12
Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Oncol (2005) 2.11
KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant (2006) 2.10
Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood (2004) 2.04
Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood (2003) 2.01
Reduced toll-like receptor 9 expression on peripheral CD14+ monocytes of chronic hepatitis B patients and its restoration by effective therapy. Antivir Ther (2014) 1.99
An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci U S A (2006) 1.99
Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol Blood Marrow Transplant (2008) 1.96
An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood (2006) 1.95
Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. Blood (2013) 1.94
High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis (2002) 1.93
A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med (2006) 1.91
Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood (2011) 1.90
Evaluation of published single nucleotide polymorphisms associated with acute GVHD. Blood (2012) 1.88
High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology (2006) 1.87
Epidemiologic features of Kawasaki disease in Taiwan, 2003-2006. Pediatrics (2009) 1.85
RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. Gastroenterology (2005) 1.85
Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis (2006) 1.84
Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol (2010) 1.84
MHC haplotype matching for unrelated hematopoietic cell transplantation. PLoS Med (2007) 1.83
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol (2009) 1.82
Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology (2008) 1.81
Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol (2002) 1.80
Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood (2002) 1.80
Benchmarks in clinical productivity: a national comprehensive cancer network survey. J Oncol Pract (2007) 1.79
Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther (2011) 1.77
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood (2011) 1.76
Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B. J Gastroenterol (2002) 1.76
Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels. Hepatology (2007) 1.75
High HLA-DP Expression and Graft-versus-Host Disease. N Engl J Med (2015) 1.74
Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood (2003) 1.72
Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology (2010) 1.68
Characterization of severe acute respiratory syndrome coronavirus genomes in Taiwan: molecular epidemiology and genome evolution. Proc Natl Acad Sci U S A (2004) 1.66
Estrogen receptor α represses transcription of HBV genes via interaction with hepatocyte nuclear factor 4α. Gastroenterology (2012) 1.66
A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood (2007) 1.66
Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 1.65